Meeting
2018 ASCO Annual Meeting
Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in the randomized phase III FRESCO trial.
Authors
Yu-Xian Bai
Harbin Medical University Cancer Hospital, Department of Medical Oncology, Harbin, China
Yu-Xian Bai , Shukui Qin , Jin Li , Yanhong Deng , Lei Yang , Rui-hua Xu , Haijun Zhong , Zhendong Chen , Hongming Pan , Weijian Guo , Yongqian Shu , Cike Peng , Yun Chen , Hongyan Li , Ning Wang , Xiaojun Guo , Wei Wang , Songhua Fan , Jian-Ming Xu , Lin Shen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl; abstr 3544)
DOI
10.1200/JCO.2018.36.15_suppl.3544
Abstract #
3544
Poster Bd #
37
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib + best supportive care (BSC) compared with placebo + BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial.
First Author: Sebastian Stintzing
Poster
2021 Gastrointestinal Cancers Symposium
FRESCO-2: A global phase III study of the efficacy and safety of fruquintinib in patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Arvind Dasari
Poster
2023 ASCO Annual Meeting
Subgroup analyses of safety and efficacy by number and types of prior lines of treatment in FRESCO-2, a global phase III study of fruquintinib in patients with refractory metastatic colorectal cancer.
First Author: Arvind Dasari